Molecule News and Research

RSS

Direct RNA sequencing performed using Helicos’ True Single Molecule Sequencing technology

Helicos BioSciences Corporation a life science company focused on innovative genetic analysis technologies, today announced the publication of a landmark study in which Helicos’ True Single Molecule Sequencing (tSMS)™ technology was used to directly sequence individual molecules of RNA. The paper appeared yesterday in the on-line edition of Nature and will appear in an upcoming 2009 print issue of Nature.

24 Sep 2009

PNNL Department of Energy researcher earns prestigious NIH Director's New Innovator Award

An analytical chemist at the Department of Energy's Pacific Northwest National Laboratory has been recognized with a National Institutes of Health Director's New Innovator Award. The award will support Wei-Jun Qian's drive to make new research and clinical diagnostic tools that are dramatically more sensitive, reliable and faster than current technologies.

24 Sep 2009

NIH awards $2.5 million grant to University of Utah cardiologist

A pioneering model that a University of Utah cardiologist proposes as a cause of heart disease is the kind of creative thinking the National Institutes of Health (NIH) likes to see-and reward with one of its most prestigious honors, a $2.5 million 2009 Pioneer Award.

24 Sep 2009

Lux Biosciences announces results of its LX214 human safety study for dry eye syndrome

Lux Biosciences, Inc. a privately held biotechnology company focused on the treatment of ophthalmic diseases, today announced results from a Phase 1 human safety and an open-label pilot efficacy study of the company’s potential best-in-class therapy for dry eye, LX214 (topical mixed nanomicellar formulation of voclosporin).

24 Sep 2009

DISC1 linked to proper development and migration of neurons in the brain

Scientists now have a better understanding of a perplexing gene that is associated with susceptibility for a wide spectrum of severely debilitating mental illnesses. Two independent research studies published by Cell Press in the September 24th issue of the journal Neuron provide fascinating insight into the molecular mechanisms that link disrupted-in-schizophrenia 1 (DISC1) with the proper development and migration of neurons in the hippocampus, a brain area involved in learning and memory and associated with the pathology of schizophrenia.

24 Sep 2009

TSPs can block cancer-triggering proto-oncogenes

A tiny bit of genetic material with no previously known function may hold the key to stopping the spread of cancer, researchers at Yale School of Medicine and Sichuan University in Chengdu, China report in two papers in the September 7-11 issue of Proceedings of the National Academy of Sciences.

24 Sep 2009

NIH grants $2.5M for the study of physical forces on cell function

The National Institutes of Health today announced an award of $2.5 million to a team led by Boston University biomedical engineer Bela Suki that will study the role of physical forces on cell function, with the goal of understanding the possible roles of these forces in diseases like atherosclerosis, neuro-degenerative diseases, metabolic disorders, aging and cancer.

24 Sep 2009

Hsp-27 protein helps identify aggressive prostate cancer

CANCER RESEARCH UK scientists have discovered a molecular 'flag' that predicts survival from prostate cancer at diagnosis, reveals a study published in the British Journal of Cancer.

24 Sep 2009

Magnetic nanoworms and nanocrystals deliver siRNA to tumors

Small pieces of nucleic acid known as short interfering RNAs, or siRNAs, can turn off the production of specific proteins, a property that makes them one of the more promising new classes of anticancer drugs in development. Indeed, at least two siRNA-based anticancer therapies, both delivered to tumors in nanoparticles, have begun human clinical trials.

23 Sep 2009

FDA accepts Sangamo's IND for repeat-dosing in Phase 1 clinical trial of SB-728-T ZFN-based therapeutic

Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that the US Food and Drug Administration (FDA) has reviewed and accepted an Investigational New Drug (IND) application to initiate an open-label, repeat-dosing Phase 1 clinical trial (SB-728-T-902) of the company's ZFN-based therapeutic, SB-728-T. A single dose Phase 1 clinical study of SB-728-T was initiated in February 2009 and is ongoing at the University of Pennsylvania.

23 Sep 2009

Technological and scientific initiatives from Helicos BioSciences Corporation

Helicos BioSciences Corporation provided updates on recent scientific findings and progress on Helicos’s technology initiatives. Speaking at the Personal Genomes conference in Cold Spring Harbor, NY, and the CHI Next Generation Sequencing conference in Providence, RI, Patrice Milos, Ph.D. Vice President and Chief Scientific Officer provided an overview of recent technological and scientific initiatives underway at Helicos.

23 Sep 2009

Drugs blocking the effects of ACh may prevent cancer

By seeing what substances and molecules affect the development of our diseases, we can develop drugs that prevent or cure diseases. In her dissertation at Kalmar University in Sweden, Ann Novotny has found that the signal molecule acetylcholine (ACh) is important for the progress of cancer of the large intestine and colon, knowledge that is important to factor in when developing drugs that block the effects of Ach on tumor cells.

23 Sep 2009

Drug trial for OSI-906 begins

TGen Clinical Research Services at Scottsdale Healthcare today announced the start of a clinical trial for a drug designed to combat adrenocortical carcinoma (ACC), a rare but deadly cancer that attacks the adrenal glands.

23 Sep 2009

Bio-Path Holdings to develop liposome tumor targeting technology

Bio-Path Holdings, Inc. (OTCBB: BPTH), a publicly traded biotechnology company with drug development operations in Houston, Texas, announced today the Company has executed an exclusive license with The University of Texas M. D. Anderson Cancer Center to develop liposome tumor targeting technology. Bio-Path is currently developing a neutral-lipid based liposome delivery technology for nucleic acid cancer drugs (including antisense and siRNA molecules).

23 Sep 2009

Declining performance of muscles linked to harmful byproducts of air we breathe

If you think the air outside is polluted, a new research report in the September 2009 issue of the journal Genetics (http://www.genetics.org) might make you to think twice about the air inside our bodies too. That's because researchers show how about 3 percent of the air we breathe gets converted into harmful superoxides, which ultimately harm our muscles.

23 Sep 2009

$1.2 million grant to study centrosomes and cilia and their connections to human disease

If you don't know how a human cell is supposed to work, it's hard to offer a good explanation when the cell goes haywire -- as it does in cancer. That's why a Florida State University College of Medicine researcher has been awarded a $1.2 million grant to explore the role of centrosomes and cilia in cell division and development and their connections to human disease.

22 Sep 2009

Advaxis' patent approval enables the development of new vaccines with additional properties

The United States Patent and Trademark Office (USPTO) has granted and issued Advaxis, Inc. (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) vaccine company, patent 7,588,930 “Compositions and Methods for Enhancing Immunogenicity of Antigens.” This patent expands the Company’s intellectual property portfolio to cover another family of adjuvant proteins based upon the Lm protein Act-A.

22 Sep 2009

Updates from Pacific Biosciences to its commercial strategy and progress

Pacific Biosciences, a private company developing a disruptive technology platform for real-time detection of biological events at single molecule resolution, today provided a number of updates to its commercial strategy and progress.

22 Sep 2009

Cancer Research UK invests £16 million in new Drug Discovery Programes at Manchester and Glasgow

CANCER RESEARCH UK is set to extend its drug discovery effort by investing up to £16 million in two new Drug Discovery Programmes at the Paterson Institute for Cancer Research in Manchester and the Beatson Institute for Cancer Research in Glasgow.

22 Sep 2009

Molecule responsible for neuronal branches identifed

The human brain consists of about 100 billion (1011) neurons, which altogether form about 100 trillion (1014) synaptic connections with each other. A crucial mechanism for the generation of this complex wiring pattern is the formation of neuronal branches. The neurobiologists Dr. Hannes Schmidt and Professor Fritz G. Rathjen at the Max Delbr-ck Center for Molecular Medicine (MDC) Berlin-Buch, Germany, have now discovered a molecule that regulates this vital process. At the same time they have succeeded in elucidating the signaling cascade induced by this molecule (PNAS, Early Edition, 2009, doi:10.1073).

22 Sep 2009